RT Journal Article
SR Electronic
A1 Bankhead, Charles
T1 Advances in NSCLC
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 4
SP 20
OP 21
DO 10.1177/155989771104012
UL http://mdc.sagepub.com/content/11/4/20.abstract
AB The era of targeted therapy has arrived for lung cancer and has made an unprecedented impact on outcomes, including survival. Choosing therapy on the basis of mutation testing has dramatically increased survival expectations from a few months with conventional chemotherapy to as much as 3 years with targeted agents.